Citius pharmaceuticals completes enrollment in pivotal phase 3 trial of its mino-lok® therapeutic to salvage catheters

Topline results expected 2q 2024 study enrolled a total of 241 patients; 109 catheter failures observed first-and-only antibiotic lock solution in development to salvage catheters in patients with crbsi cranford, n.j., jan. 2, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has completed enrollment in its pivotal phase 3 clinical trial for mino-lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.
CTXR Ratings Summary
CTXR Quant Ranking